Thomas M. MacDonald

20.5k total citations · 2 hit papers
357 papers, 12.9k citations indexed

About

Thomas M. MacDonald is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Thomas M. MacDonald has authored 357 papers receiving a total of 12.9k indexed citations (citations by other indexed papers that have themselves been cited), including 143 papers in Cardiology and Cardiovascular Medicine, 72 papers in Endocrinology, Diabetes and Metabolism and 59 papers in Surgery. Recurrent topics in Thomas M. MacDonald's work include Blood Pressure and Hypertension Studies (83 papers), Hormonal Regulation and Hypertension (46 papers) and Inflammatory mediators and NSAID effects (33 papers). Thomas M. MacDonald is often cited by papers focused on Blood Pressure and Hypertension Studies (83 papers), Hormonal Regulation and Hypertension (46 papers) and Inflammatory mediators and NSAID effects (33 papers). Thomas M. MacDonald collaborates with scholars based in United Kingdom, United States and Germany. Thomas M. MacDonald's co-authors include Pitt Lim, Isla S. Mackenzie, Li Wei, Andrew D. Morris, S. V. Morant, Peter T. Donnan, Allan D. Struthers, Brian R. Walker, Wei Li and Josie Evans and has published in prestigious journals such as The Lancet, JAMA and Circulation.

In The Last Decade

Thomas M. MacDonald

346 papers receiving 12.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

2015 735 citations Thomas M. MacDonald, S. V. Morant et al. profile →
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease

2004 564 citations Thomas M. MacDonald et al. profile →

Peers

Countries citing papers authored by Thomas M. MacDonald

Since Specialization

Citations

This map shows the geographic impact of Thomas M. MacDonald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas M. MacDonald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas M. MacDonald more than expected).

Fields of papers citing papers by Thomas M. MacDonald

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas M. MacDonald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas M. MacDonald. The network helps show where Thomas M. MacDonald may publish in the future.

Co-authorship network of co-authors of Thomas M. MacDonald

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas M. MacDonald. A scholar is included among the top collaborators of Thomas M. MacDonald based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas M. MacDonald. Thomas M. MacDonald is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Low Achieved Systolic Blood Pressure Related to Kidney Protection in Diabetic and Non-Diabetic High-Risk Hypertensive Patients 2025 ·American Journal of Hypertension ·(unknown), Camilla Lund Søraas, Roland E. Schmieder, Kenneth Jamerson, Thomas M. MacDonald, Giuseppe Mancia, (unknown), Maria H. Mehlum, Knut Liestøl, Anne Cecilie K. Larstorp, Julian E. Mariampillai, (unknown), (unknown), Aud Høieggen, Morten Rostrup, (unknown), Michael A. Weber	1
2	Effect of timed dosing of usual antihypertensives according to patient chronotype on cardiovascular outcomes: the Chronotype sub-study cohort of the Treatment in Morning versus Evening (TIME) study 2024 ·EClinicalMedicine ·Filippo Pigazzani, Kenneth A. Dyar, S. V. Morant, Céline Vetter, Amy Rogers, Robert Flynn, David Rorie, Isla S. Mackenzie, Francesco P. Cappuccio, Roberto Manfredini, Thomas M. MacDonald	12
3	Vascular and inflammatory biomarkers of cardiovascular events in non-steroidal anti-inflammatory drug users 2024 ·European Heart Journal Open ·Ricky Vaja, (unknown), Laura Portas, Blerina Ahmetaj‐Shala, (unknown), (unknown), Jennifer K Quint, Ramzi Khamis, Adam Hartley, Thomas M. MacDonald, Isla S. Mackenzie, Nicholas S. Kirkby, Jane A. Mitchell	1
4	Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation 2024 ·Health Technology Assessment ·Isla S. Mackenzie, C J Hawkey, Ian Ford, Nicola Greenlaw, Filippo Pigazzani, Amy Rogers, Allan D. Struthers, Alan Begg, Li Wei, Anthony Avery, Jaspal Taggar, Andrew Walker, Suzanne Duce, R.J. Barr, Jennifer Dumbleton, E. Douglas Rooke, John Townend, Lewis Ritchie, Thomas M. MacDonald	2
5	Diagnosis and management of primary hyperaldosteronism in patients with hypertension: a practical approach endorsed by the British and Irish Hypertension Society 2023 ·Journal of Human Hypertension ·Luca Faconti, Spoorthy Kulkarni, Christian Delles, Vikas Kapil, Philip Lewis, Mark Glover, Thomas M. MacDonald, Ian B. Wilkinson	11
6	The Prognostic Value of Derivatives-Reactive Oxygen Metabolites (d-ROMs) for Cardiovascular Disease Events and Mortality: A Review 2022 ·Antioxidants ·Filippo Pigazzani, (unknown), Kenneth A. Dyar, Matteo Pedrelli, Gwen Kennedy, Gabriele Costantino, (unknown), Isla S. Mackenzie, Thomas M. MacDonald, Uwe J.F. Tietge, George Casella	19
7	Adverse events and overall health and well-being after COVID-19 vaccination: interim results from the VAC4COVID cohort safety study 2022 ·BMJ Open ·Amy Rogers, E. Douglas Rooke, S. V. Morant, Greg Guthrie, Alex S. F. Doney, Andrew Duncan, Isla S. Mackenzie, R.J. Barr, Filippo Pigazzani, (unknown), Thomas M. MacDonald	9
8	Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials 2021 ·BMJ ·Emily Herrett, Elizabeth Williamson, Kieran E. Brack, Danielle Beaumont, Alexander Perkins, Andrew Thayne, Haleema Shakur‐Still, Ian Roberts, Danielle Prowse, Ben Goldacre, Tjeerd van Staa, Thomas M. MacDonald, Jane Armitage, (unknown), P.A. Melrose, (unknown), (unknown), Michael Moore, Maurice Hoffman, Liam Smeeth	114
9	The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs 2021 ·Health Technology Assessment ·Emily Herrett, Elizabeth Williamson, Kieran E. Brack, Alexander Perkins, Andrew Thayne, Haleema Shakur‐Still, Ian Roberts, Danielle Prowse, Danielle Beaumont, Zahra Jamal, Ben Goldacre, Tjeerd van Staa, Thomas M. MacDonald, Jane Armitage, Michael Moore, Maurice Hoffman, Liam Smeeth	3
10	Rationale and Design of the Genotype-Blinded Trial of Torasemide for the Treatment of Hypertension (BHF UMOD) 2020 ·American Journal of Hypertension ·Linsay McCallum, Katriona Brooksbank, Alex McConnachie, Alisha Aman, Stefanie Lip, Jesse Dawson, I. MacIntyre, Thomas M. MacDonald, David R. Webb, Sandosh Padmanabhan	11
11	Spironolactone use and risk of incident cancers: a retrospective, matched cohort study 2016 ·British Journal of Clinical Pharmacology ·Isla S. Mackenzie, S. V. Morant, Li Wei, Alastair M. Thompson, Thomas M. MacDonald	41
12	Vitamin D Therapy to Reduce Blood Pressure and Left Ventricular Hypertrophy in Resistant Hypertension 2014 ·Hypertension ·Miles D. Witham, Sheila Ireland, J. Graeme Houston, Stephen J. Gandy, Shelley A. Waugh, Thomas M. MacDonald, Isla S. Mackenzie, Allan D. Struthers	52
13	Pilot Swine Flu Vaccination Active Surveillance Study: Final Results 2011 ·Drug Safety ·Deborah Layton, Moira Dryburgh, Thomas M. MacDonald, Saad Shakir, Isla S. Mackenzie	0
14	Hypertension in Octogenarians – Treatment Strategies and Challenges 2011 ·European Cardiology Review ·Isla S. Mackenzie, Thomas M. MacDonald	1
15	Participation of General Practices in a Swine Flu Vaccination Study 2010 ·Drug Safety ·Isla S. Mackenzie, Moira Dryburgh, Derek Rutherford, Thomas M. MacDonald, Saad Shakir, Deborah Layton	1
16	A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effects of Valsartan on Exercise Time in Patients with Symptomatic Heart Failure with Preserved Ejection Fraction 2009 ·European Journal of Heart Failure ·Hari Parthasarathy, Burkert Pieske, (unknown), (unknown), Patrick Brunel, Allan D. Struthers, Thomas M. MacDonald	31
17	Use of glucocorticoids and risk of cardiovascular disease in a population-based cohort study of 164,133 participants 2003 ·(unknown), Thomas M. MacDonald, Brandie Walker	1
18	The effect on toxicity on reducing the size of available paracetamol pack sizes 2001 ·Discovery Research Portal (University of Dundee) ·(unknown), James Dillon, D. Nicholas Bateman, K.J. Simpson, Thomas M. MacDonald	6
19	ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKADE: A NEW DEVELOPMENT IN CARDIOVASCULAR PHARMACOLOGY 1998 ·International Journal of Clinical Practice ·(unknown), Thomas M. MacDonald	2
20	TREATMENT OF DEPRESSION: PRESCRIPTION FOR SUCCESS? 1997 ·Discovery Research Portal (University of Dundee) ·Thomas M. MacDonald	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact